Journal: Cancer discovery
The publication highlights emerging data on next‑generation, noncovalent BTK inhibitors in chronic lymphocytic leukemia (CLL), focusing on pirtobrutinib and the newer agent rocbrutinib.
Key findings from three clinical trials:
- Frontline pirtobrutinib vs chemoimmunotherapy
In previously untreated CLL, pirtobrutinib achieved a 24‑month progression‑free survival (PFS) of 93.4%.
This compared favorably with bendamustine–rituximab, which had a 24‑month PFS of 70.7%, indicating a substantial efficacy advantage for targeted BTK inhibition over traditional chemoimmunotherapy in the frontline setting.
- Pirtobrutinib vs ibrutinib
In a mixed population of previously untreated and relapsed/refractory patients, pirtobrutinib was shown to be noninferior to the first‑generation covalent BTK inhibitor ibrutinib.
This supports pirtobrutinib as a viable alternative to ibrutinib, with the implication that noncovalent BTK inhibition can match established covalent agents in overall disease control.
- Rocbrutinib in previously treated CLL
In patients with prior therapy, rocbrutinib achieved an overall response rate of 62.5%.
This suggests meaningful clinical activity of rocbrutinib in a more heavily pretreated population and positions it as a potential successor within the noncovalent BTK inhibitor class.
Overall, the article underscores that noncovalent BTK inhibitors are demonstrating strong efficacy across treatment lines in CLL, with pirtobrutinib showing competitive or superior outcomes compared with both chemoimmunotherapy and ibrutinib, and rocbrutinib emerging as a promising next agent in this class.